CABOZANIX 60 TABLET
CABOZANTINIB
What it does
Cabozantinib is a medication used to treat certain types of cancer by targeting specific pathways that allow cancer cells to grow.
Commonly used for: advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), thyroid cancer (medullary thyroid carcinoma)
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:54:20 · updated 2026-10-20 02:32:36
Drug Interactions
16Pharmacodynamic Warnings
Cabozantinib appears in TABLE 9: Drugs that prolong the QT interval
Cabozantinib appears in TABLE 15: Drugs that cause myelosuppression
Unknown (16)
Benzodiazepines - increases exposure
Cabozantinibispredictedtoincreasetheexposureto benzodiazepines(midazolam).oTheoretical com/codemedicalapps/ cal Applications)
Cabozantinib - increases exposure
Dronedarone is predicted to increase the exposure to cabozantinib. Also see TABLE 9 p. 1519.
Cabozantinib - increases exposure
Cobicistat is predicted to increase the exposure to cabozantinib.
Cabozantinib - increases exposure
Crizotinib is predicted to increase the exposure to cabozantinib. Also see TABLE 9 p. 1519
Cabozantinib - decreases exposure
Dabrafenib is predicted to decrease the exposure to cabozantinib.
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Cabozantinib is a medication used to treat certain types of cancer by targeting specific pathways that allow cancer cells to grow.
What it treats
- advanced kidney cancer (renal cell carcinoma)
- liver cancer (hepatocellular carcinoma)
- thyroid cancer (medullary thyroid carcinoma)
How it works
It works by blocking signals that help cancer cells survive and multiply, which can slow down or stop the growth of tumors.
Who it's for
This medication is for adults with specific advanced cancers as determined by their doctor.
Cautions
- • Be cautious if taking medications that can affect heart rhythm.
- • Use with care if you are on drugs that can lower blood cell counts.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Cabozantinib
BNF-referencedCabozantinib is a targeted therapy used for the treatment of specific types of cancer. It acts as a receptor tyrosine kinase inhibitor, affecting various pathways involved in tumor growth and metastasis. Its primary indications include progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma, advanced renal cell carcinoma, and hepatocellular carcinoma. The drug is initiated by a specialist and requires careful monitoring due to its potential side effects, which can include hypertension and gastrointestinal issues.
Indications
- Progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma
- Advanced renal cell carcinoma
- Hepatocellular carcinoma
Dosage
Adults: The usual starting dose is 140 mg once daily for medullary thyroid carcinoma, 60 mg once daily for advanced renal cell carcinoma, and 40 mg once daily for hepatocellular carcinoma. For dose adjustments, refer to product literature following treatment interruptions due to side effects.
Mechanism of action
Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2, leading to the suppression of metastasis, angiogenesis, and oncogenesis.
Pharmacodynamics
Cabozantinib exerts its effects by inhibiting receptor tyrosine kinases, thereby interrupting the signaling pathways that promote tumor growth and vascular development. This results in reduced tumor cell proliferation and metastasis, as well as decreased angiogenesis, which is critical for tumor survival and expansion.
Pharmacokinetics
Cabozantinib is administered orally and undergoes extensive hepatic metabolism. Its pharmacokinetics can be affected by food intake, and it is primarily eliminated via the liver. The drug has a half-life that allows for once-daily dosing. Monitoring for drug interactions is essential as various medications can alter its exposure.
Adverse effects
- abscess
- alopecia
- anaemia
- anxiety
- appetite decreased
- arrhythmias
- arthralgia
- asthenia
- chills
- cholelithiasis
- confusion
- constipation
- cough
- dehydration
- depression
- diarrhoea
- dizziness
- dry mouth
- dyslipidaemia
- dysphagia
- dysphonia
- dyspnoea
- dysuria
- ear pain
- electrolyte imbalance
- embolism
- thrombosis
- encephalopathy
- fistula
- gastrointestinal discomfort
- gastrointestinal disorders
- haemorrhage
- hair changes
- headache
- healing impaired
- hyperbilirubinaemia
- hyperglycaemia
- hypertension
- hypoalbuminaemia
- hypoglycaemia
- hypotension
- hypothyroidism
- increased risk of infection
- lymphedema
- mucositis
- muscle spasms
- nausea
- nerve disorders
- neutropenia
- oedema
- oral disorders
- oropharyngeal pain
Interactions
- dronedarone+cabozantinib: Unknown (increases exposure)
- cabozantinib+midazolam: Unknown (increases exposure)
- cabozantinib+benzodiazepines: Unknown (increases exposure)
- cobicistat+cabozantinib: Unknown (increases exposure)
- cabozantinib+combined hormonal contraceptives: Unknown (affects effects)
- crizotinib+cabozantinib: Unknown (increases exposure)
- dabrafenib+cabozantinib: Unknown (decreases exposure)
- grapefruit juice+cabozantinib: Unknown (increases exposure)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Cabozantinib
PubChem CID 25102847Molecular formula: C28H24FN3O5
Mechanism of action
Cabozantinib inhibits specific receptor tyrosine kinases such as VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, RET, MET, and TIE-2.
Pharmacodynamics
Cabozantinib suppresses metastasis, angiogenesis, and oncognesis by inhibiting receptor tyrosine kinases.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.